Johnson & Johnson (JNJ): Price and Financial Metrics

Johnson & Johnson (JNJ): $165.18

-1.41 (-0.85%)

POWR Rating

Component Grades













JNJ Stock Summary

  • Johnson & Johnson's market capitalization of $437,911,771,880 is ahead of 99.75% of US-listed equities.
  • JNJ's went public 35.33 years ago, making it older than 92.8% of listed US stocks we're tracking.
  • The volatility of Johnson & Johnson's share price is greater than that of only 3.24% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to JNJ, based on their financial statements, market capitalization, and price volatility, are JPM, WMT, MA, UNH, and DIS.
  • JNJ's SEC filings can be seen here. And to visit Johnson & Johnson's official web site, go to

JNJ Stock Price Chart Interactive Chart >

Price chart for JNJ

JNJ Price/Volume Stats

Current price $165.18 52-week high $173.65
Prev. close $166.59 52-week low $133.65
Day low $164.62 Volume 7,232,900
Day high $166.28 Avg. volume 8,272,644
50-day MA $161.84 Dividend yield 2.45%
200-day MA $153.30 Market Cap 434.87B

Johnson & Johnson (JNJ) Company Bio

Johnson & Johnson researches and develops, manufactures, and sells various products in the health-care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Some of its well-known brands include Tylenol-fever, Listerine-bad breath, Splenda-no-calorie sweetener, Neutrogena-skin care, Pepcid-heartburn, Zyrtec - allergy, Motrin-ibuprofen, Sudafed-allergy, and plenty more. The company was founded in 1885 and is based in New Brunswick, New Jersey.

JNJ Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$165.18$73.32 -56%

Below please find a table outlining a discounted cash flow forecast for JNJ, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Johnson & Johnson ranked in the 35th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 55.83%. As for the metrics that stood out in our discounted cash flow analysis of Johnson & Johnson, consider:

  • As a business, JNJ is generating more cash flow than 98.14% of positive cash flow stocks in the Healthcare.
  • The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than only 23.35% of the free cash flow producing stocks we're observing.
  • JNJ's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 38.15% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

ICUI, ABC, AMPH, AZN, and NVS can be thought of as valuation peers to JNJ, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

JNJ Latest News Stream

Event/Time News Detail
Loading, please wait...

JNJ Latest Social Stream

Loading social stream, please wait...

View Full JNJ Social Stream

Latest JNJ News From Around the Web

Below are the latest news stories about Johnson & Johnson that investors may wish to consider to help them evaluate JNJ as an investment opportunity.

JNJ COVID-19 vaccine: South Africa to resume rollout

The South African government has decided to lift the suspension imposed on the COVID-19 vaccine developed by Johnson & Johnson (JNJ), the Mail & Guardian reported.Soon after the U.S. recommended a pause on the JNJ’s vaccine citing rare cases of blood clots, South Africa also halted its use. The country had only...

Seeking Alpha | April 22, 2021

Dividends Are Definitely Back - April 2021 Brings Roaring Dividends

Photo by designer491/iStock via Getty Images Dividend investing community, I had to write this article. The blood or "dividends" are pumping through my veins. Dividend aristocrats are increasing their dividends and beating expectations. In addition, companies are increasing dividends that I would not have seen coming. Therefore, this bodes the...

Dividend Diplomats on Seeking Alpha | April 21, 2021

OCGN Stock: The Huge COVAXIN News Sending Ocugen Climbing Today

OCGN stock is gaining Wednesday morning on news that Bharat Biotech's COVAXIN has an overall 78% efficacy rate.

Robert Lakin on InvestorPlace | April 21, 2021

Federal Inspectors Say More Vaccines at Troubled Plant May Be Contaminated

Last month, up to 15 million doses of Johnson & Johnson’s vaccine had to be discarded at Emergent’s factory in Baltimore. A new report says problems were not fully investigated and other doses may be compromised.

New York Times | April 21, 2021

Minneapolis, Johnson & Johnson, YOLO: Your Wednesday Evening Briefing

Here’s what you need to know at the end of the day.

New York Times | April 21, 2021

Read More 'JNJ' Stories Here

JNJ Price Returns

1-mo 2.02%
3-mo 1.63%
6-mo 15.23%
1-year 9.09%
3-year 41.97%
5-year 66.65%
YTD 5.61%
2020 10.82%
2019 16.22%
2018 -5.13%
2017 24.43%
2016 15.33%

JNJ Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full JNJ Dividend History

Continue Researching JNJ

Want to see what other sources are saying about Johnson & Johnson's financials and stock price? Try the links below:

Johnson & Johnson (JNJ) Stock Price | Nasdaq
Johnson & Johnson (JNJ) Stock Quote, History and News - Yahoo Finance
Johnson & Johnson (JNJ) Stock Price and Basic Information | MarketWatch

Page generated in 0.9689 seconds.